Long-Term Outcomes for Patients with Prostate Cancer Having Intermediate and High-Risk Disease, Treated with Combination External Beam Irradiation and Brachytherapy
Figure 4
Freedom from biochemical progression (PSA 0.2 ng/mL, nadir +2) with or without adjuvant hormonal therapy (univariate analyis).